Orphalan announces China NMPA™s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (Orphalan or the Company),...
Orphalan announces US commercial launch of Cuvriorâ„¢ for the treatment of Wilson disease
Paris, France 30 September, 2022 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the publication of the Company’s phase III CHELATE trial in The Lancet Gastroenterology & Hepatology1, presenting the efficacy and tolerability of trientine tetrahydrochloride for the treatment of Wilson's disease over a period of one year.
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global Wilson’s Registry will provide an international...
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease — Data from the company’s CHELATE trial to be presented today during an oral...